Exploring the Role of Eosinophils and IL-5 Inhibitors in Severe Asthma and Associated Conditions Evaluation (ID: i752a) Survey

Question Title

* 3. Which of the following most closely describes your practice setting?

Academic institution

Managed care

Private practice

Hospital

Research & basic science

Industry

Other (please specify)

Question Title

* 4. How many patients with severe asthma and associated eosinophil-mediated conditions do you treat each week?

1 - 5

6 - 10

11 - 20

≥21

I am not directly involved in patient care

Question Title

* 5. Of the patients you will see in the next week, about how many will benefit from the information you learned today?

1 - 5

6 - 10

11 - 20

≥21

I am not directly involved in patient care

Question Title

* 6. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

Improved diagnosis and severity assessments

Personalize therapy based on guideline-driven treatment strategies

Improved utilization of new and emerging treatments based on safety and efficacy data

Best practices of my colleagues and leaders

I do not plan to make any changes, as my current practice is consistent with the information presented.

Other (please explain)

Question Title

* 7. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 8. How committed are you to making changes in your practice based on your participation in this activity?

Very committed

Committed

Neutral

Not committed

I do not plan to make changes

Question Title

* 9. What barriers do you see to making changes in your practice?

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Cost of medication

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Other (please explain)

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating.
Bradley E. Chipps, MD, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the material	Presented the material Strongly agree	Presented the material Agree	Presented the material Neutral	Presented the material Disagree	Presented the material Strongly disagree
Avoided commercial bias	Avoided commercial bias Strongly agree	Avoided commercial bias Agree	Avoided commercial bias Neutral	Avoided commercial bias Disagree	Avoided commercial bias Strongly disagree

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating.
Monica Kraft, MD, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the material	Presented the material Strongly agree	Presented the material Agree	Presented the material Neutral	Presented the material Disagree	Presented the material Strongly disagree
Avoided commercial bias	Avoided commercial bias Strongly agree	Avoided commercial bias Agree	Avoided commercial bias Neutral	Avoided commercial bias Disagree	Avoided commercial bias Strongly disagree

Question Title

* 12. Please rate your level of agreement by checking the appropriate rating.
Michael Wechsler, MD, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the material	Presented the material Strongly agree	Presented the material Agree	Presented the material Neutral	Presented the material Disagree	Presented the material Strongly disagree
Avoided commercial bias	Avoided commercial bias Strongly agree	Avoided commercial bias Agree	Avoided commercial bias Neutral	Avoided commercial bias Disagree	Avoided commercial bias Strongly disagree

Question Title

* 13. After participating in today’s activity, I am now able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Describe the role of eosinophilia in severe asthma and eosinophilic granulomatosis with polyangiitis	Describe the role of eosinophilia in severe asthma and eosinophilic granulomatosis with polyangiitis Strongly agree	Describe the role of eosinophilia in severe asthma and eosinophilic granulomatosis with polyangiitis Agree	Describe the role of eosinophilia in severe asthma and eosinophilic granulomatosis with polyangiitis Neutral	Describe the role of eosinophilia in severe asthma and eosinophilic granulomatosis with polyangiitis Disagree	Describe the role of eosinophilia in severe asthma and eosinophilic granulomatosis with polyangiitis Strongly disagree
Explain why rare orphan diseases and severe asthma comorbidities have an impact on treatment of severe asthma	Explain why rare orphan diseases and severe asthma comorbidities have an impact on treatment of severe asthma Strongly agree	Explain why rare orphan diseases and severe asthma comorbidities have an impact on treatment of severe asthma Agree	Explain why rare orphan diseases and severe asthma comorbidities have an impact on treatment of severe asthma Neutral	Explain why rare orphan diseases and severe asthma comorbidities have an impact on treatment of severe asthma Disagree	Explain why rare orphan diseases and severe asthma comorbidities have an impact on treatment of severe asthma Strongly disagree
Differentiate between biologic therapies and evaluate their impact on lung function, disease exacerbation, and dependence on oral corticosteroids	Differentiate between biologic therapies and evaluate their impact on lung function, disease exacerbation, and dependence on oral corticosteroids Strongly agree	Differentiate between biologic therapies and evaluate their impact on lung function, disease exacerbation, and dependence on oral corticosteroids Agree	Differentiate between biologic therapies and evaluate their impact on lung function, disease exacerbation, and dependence on oral corticosteroids Neutral	Differentiate between biologic therapies and evaluate their impact on lung function, disease exacerbation, and dependence on oral corticosteroids Disagree	Differentiate between biologic therapies and evaluate their impact on lung function, disease exacerbation, and dependence on oral corticosteroids Strongly disagree

Question Title

* 14. The content presented:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Enhanced my current knowledge base	Enhanced my current knowledge base Strongly agree	Enhanced my current knowledge base Agree	Enhanced my current knowledge base Neutral	Enhanced my current knowledge base Disagree	Enhanced my current knowledge base Strongly disagree
Addressed pressing questions	Addressed pressing questions Strongly agree	Addressed pressing questions Agree	Addressed pressing questions Neutral	Addressed pressing questions Disagree	Addressed pressing questions Strongly disagree
Was scientifically rigorous and evidence-based	Was scientifically rigorous and evidence-based Strongly agree	Was scientifically rigorous and evidence-based Agree	Was scientifically rigorous and evidence-based Neutral	Was scientifically rigorous and evidence-based Disagree	Was scientifically rigorous and evidence-based Strongly disagree
Avoided commercial bias or influence	Avoided commercial bias or influence Strongly agree	Avoided commercial bias or influence Agree	Avoided commercial bias or influence Neutral	Avoided commercial bias or influence Disagree	Avoided commercial bias or influence Strongly disagree

Exploring the Role of Eosinophils and IL-5 Inhibitors in Severe Asthma and Associated Conditions Evaluation (ID: i752a)

Question Title

* 1. Contact information

Question Title

* 2. What is your degree?

Question Title

* 3. Which of the following most closely describes your practice setting?

Question Title

* 4. How many patients with severe asthma and associated eosinophil-mediated conditions do you treat each week?

Question Title

* 5. Of the patients you will see in the next week, about how many will benefit from the information you learned today?

Question Title

* 6. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

Question Title

* 7. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 8. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 9. What barriers do you see to making changes in your practice?

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating.
Bradley E. Chipps, MD, effectively:

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating.
Monica Kraft, MD, effectively:

Question Title

* 12. Please rate your level of agreement by checking the appropriate rating.
Michael Wechsler, MD, effectively:

Question Title

* 13. After participating in today’s activity, I am now able to:

Question Title

* 14. The content presented:

Question Title

* 15. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 16. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities:

Question Title

* 1. Contact information

Question Title

* 2. What is your degree?

Question Title

* 3. Which of the following most closely describes your practice setting?

Question Title

* 4. How many patients with severe asthma and associated eosinophil-mediated conditions do you treat each week?

Question Title

* 5. Of the patients you will see in the next week, about how many will benefit from the information you learned today?

Question Title

* 6. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

Question Title

* 7. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 8. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 9. What barriers do you see to making changes in your practice?

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating. Bradley E. Chipps, MD, effectively:

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating. Monica Kraft, MD, effectively:

Question Title

* 12. Please rate your level of agreement by checking the appropriate rating. Michael Wechsler, MD, effectively:

Question Title

* 13. After participating in today’s activity, I am now able to:

Question Title

* 14. The content presented:

Question Title

* 15. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 16. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities:

* 10. Please rate your level of agreement by checking the appropriate rating.
Bradley E. Chipps, MD, effectively:

* 11. Please rate your level of agreement by checking the appropriate rating.
Monica Kraft, MD, effectively:

* 12. Please rate your level of agreement by checking the appropriate rating.
Michael Wechsler, MD, effectively: